FDMT

+ Watchlist + Portfolio

4D Molecular Therapeutics, Inc.

Regulated industry Sells to businesses Development stageTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $13.84
52-Week Range: $6.96 – $16.93
Market Cap: $755.19M
P/E (TTM): —
EPS (TTM): -2.63
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 1.85
PEG Ratio: —
Return on Equity: -43.25%
Return on Assets: -25.09%
Gross Margin: -157.70%
Operating Margin: -2037.16%
Profit Margin: -194.74%
Current Ratio: 8.03
Debt/Equity: 0.10
Total Debt: $39.22M
Free Cash Flow: $-90.77M
Revenue Growth: 25106.70%
Earnings Growth: —
Enterprise Value: $433.07M

FDMT Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$3.13M	$20.72M	$37.00K	$85.21M
Research & Development	$80.25M	$97.10M	$141.30M	$195.70M
Selling, General & Admin	$32.91M	$36.49M	$46.58M	$49.06M
Operating Expenses	$113.16M	$133.59M	$187.88M	$244.76M
Operating Income	-$110.03M	-$112.87M	-$187.84M	-$159.55M
EBITDA	-$106.15M	-$107.12M	-$181.14M	-$151.92M
Pretax Income	-$107.49M	-$100.84M	-$160.87M	-$140.11M
Net Income	-$107.49M	-$100.84M	-$160.87M	-$140.11M
Diluted EPS	-3.32	-2.58	-2.98	-2.42
Diluted Shares	32.35M	39.13M	53.94M	57.93M

FDMT Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$52.35M	$249.11M	$149.34M	$60.24M
Receivables	$0.00	—	—	—
Current Assets	$220.51M	$296.59M	$434.93M	$413.13M
Total Assets	$261.85M	$339.89M	$560.38M	$566.71M
Current Liabilities	$15.73M	$18.95M	$29.15M	$43.98M
Total Debt	$16.12M	$14.67M	$24.61M	$21.41M
Total Liabilities	$30.51M	$32.06M	$49.78M	$61.05M
Retained Earnings	-$314.49M	-$415.33M	-$576.20M	-$716.30M
Shareholders' Equity	$231.34M	$307.83M	$510.61M	$505.66M
Working Capital	$204.78M	$277.64M	$405.78M	$369.15M

FDMT Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$86.69M	-$75.79M	-$134.59M	-$109.08M
Capital Expenditure	-$11.54M	-$2.77M	-$3.79M	-$536.00K
Free Cash Flow	-$98.22M	-$78.56M	-$138.37M	-$109.62M
Depreciation & Amortisation	$3.88M	$5.75M	$6.71M	$7.63M
Stock-Based Compensation	$17.12M	$19.66M	$26.12M	$22.02M
Investing Cash Flow	-$17.05M	$115.72M	-$302.44M	-$92.97M
Financing Cash Flow	$3.08M	$156.83M	$337.25M	$112.96M
Net Change in Cash	-$100.65M	$196.76M	-$99.77M	-$89.09M

FDMT Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$14.00K	$15.00K	$90.00K	$85.09M	$3.05M	$3.78M
Research & Development	$40.70M	$47.95M	$49.44M	$57.61M	$64.98M	$68.28M
Selling, General & Admin	$12.94M	$11.52M	$11.84M	$12.77M	$11.69M	$12.52M
Operating Expenses	$53.63M	$59.47M	$61.27M	$70.38M	$76.67M	$80.81M
Operating Income	-$53.62M	-$59.46M	-$61.19M	$14.71M	-$73.62M	-$77.03M
EBITDA	-$51.87M	-$57.57M	-$59.18M	$16.70M	-$71.56M	-$74.94M
Pretax Income	-$47.97M	-$54.66M	-$56.88M	$19.40M	-$68.76M	-$72.94M
Net Income	-$47.97M	-$54.66M	-$56.88M	$19.40M	-$68.76M	-$72.94M
Diluted EPS	-0.86	-0.98	-1.01	—	-1.01	-1.04
Diluted Shares	55.74M	55.93M	56.13M	—	68.06M	70.27M

FDMT Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$133.53M	$77.16M	$48.55M	$60.24M	$72.49M	$70.37M
Receivables	—	—	—	—	—	$4.61M
Current Assets	$332.57M	$303.29M	$312.38M	$413.13M	$405.36M	$382.96M
Total Assets	$515.73M	$473.64M	$423.98M	$566.71M	$512.90M	$492.62M
Current Liabilities	$26.90M	$34.68M	$37.11M	$43.98M	$43.40M	$47.67M
Long-Term Debt	—	—	—	—	—	$19.59M
Total Debt	$23.85M	$23.08M	$22.26M	$21.41M	$20.54M	$39.22M
Total Liabilities	$46.01M	$52.75M	$55.00M	$61.05M	$61.07M	$84.96M
Retained Earnings	-$624.17M	-$678.83M	-$735.70M	-$716.30M	-$785.06M	-$858.00M
Shareholders' Equity	$469.72M	$420.89M	$368.98M	$505.66M	$451.84M	$407.66M
Working Capital	$305.67M	$268.61M	$275.27M	$369.15M	$361.96M	$335.28M

FDMT Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$47.76M	-$43.38M	-$46.50M	$28.55M	-$68.13M	-$70.00M
Capital Expenditure	-$631.00K	-$66.00K	—	—	—	—
Free Cash Flow	-$48.39M	-$43.44M	-$46.41M	$28.62M	-$68.13M	-$70.05M
Depreciation & Amortisation	$1.75M	$1.89M	$2.00M	$1.98M	$2.06M	$2.09M
Stock-Based Compensation	$6.99M	$4.96M	$4.52M	$5.55M	$4.45M	$5.88M
Investing Cash Flow	$31.95M	-$13.85M	$17.78M	-$128.85M	$68.89M	$25.54M
Financing Cash Flow	$0.00	$862.00K	$116.00K	$111.98M	$11.48M	$42.34M
Net Change in Cash	-$15.81M	-$56.37M	-$28.60M	$11.69M	$12.25M	-$2.12M

Market Snapshot

About

4D Molecular Therapeutics, Inc. is a clinical-stage gene therapy company developing treatments for severe cardiovascular and pulmonary diseases. The company's proprietary platform creates targeted and evolved adeno-associated virus (AAV) vectors designed for specific tissues and disease applications. 4D Molecular Therapeutics' lead programs address conditions including Fabry disease, cystic fibrosis, and pulmonary arterial hypertension. The company's Therapeutic Vector Evolution platform combines directed evolution with machine learning to optimize vector performance. Clinical trials are evaluating the safety and efficacy of these novel gene therapy candidates.